logo-loader
viewNetscientific PLC

NetScientific boss proud of cancer diagnostic tool's achievements

NetScientific PLC (LON:NSCI) boss François Martelet talks Proactive through news its flagship company Vortex Biosciences has begun the commercial launch of its VTX1 Liquid Biopsy system.
It's the first time  Netscientific has been able to market a cancer diagnostic instrument and it has been executed on time and in line with market expectations, he says.
"It's a very fast and simple way to isolate and collect intact CTCs directly from the whole blood," he says.

Quick facts: Netscientific PLC

Price: 6 GBX

AIM:NSCI
Market: AIM
Market Cap: £4.71 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Netscientific PLC named herein, including the promotion by the Company of Netscientific PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19

2 min read